Swetha Kambhampati (@SwethaKMD) profile picture

Assistant Professor at City of Hope; Alum: UCSF heme/onc, Hopkins IM, Stanford Med; Interested in lymphoma and CART

Los Angeles, CA
Joined February 2010
Swetha Kambhampati retweeted
Developing the treatments of tomorrow is hard work. @DoctorAKrishnan, M.D., and @elizabeth_budde, M.D., Ph.D., are leading a few clinical trials related to bispecific antibodies and their ability to target cancer cells more precisely than chemo. https://teapawt.net/t.co/to7k4B0llm #HemOnc
2
7
720
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in patients with relapsed or refractory LBCL, according to the primary OS analysis of the phase III ZUMA-7 study released by @KitePharma. bloodcancerstoday.com/post/z…
1
2
298
🔊OUT NOW: This all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, about the cost effectiveness of pola-R-CHP in relation to other therapies for DLBCL. @SocietyofHemOnc bloodcancerstoday.com/podcas…
2
4
10
1,062
Huge news! ZUMA-7 trial shows axi-cel improves overall survival in patients with second-line aggressive lymphoma, compared to chemo/autoSCT. Statistically significant, which should end the “try chemo first” argument. Full data to be presented in the next few months. #lymsm
#NEWS: Today, we announced the primary overall survival (OS) analysis results, a key secondary endpoint, of our Phase 3 study of CAR T-cell therapy for initial treatment of relapsed/refractory large B-cell lymphoma.

1
8
63
7,477
Swetha Kambhampati retweeted
Dr. Ayushi Chauhan @Chauhan_AF from @GACancerCenter named the 2023 Stephanie A. Gregory Distinguished Scholar by the Lymphoma Research Foundation @lymphoma. A brilliant young investigator. Very proud of her accomplishments.
3
3
1
26
3,379
🔊Coming Thursday, 3/23: An all-new episode of The HemOnc Pulse features host @chadinabhan speaking with @SwethaKMD of @cityofhope and Nikhil Thiruvengadam, MD, of @UCSF about modeling the cost effectiveness of pola-R-CHP in relation to other DLBCL therapies. @SocietyofHemOnc
5
2
12
4,523
Swetha Kambhampati retweeted
Excited the City of Hope experience with bridging therapy prior to CAR T for LBCL is published. Thanks for the collaboration between @COH_RadOnc and @COHMedOnc. Stay tuned for our prospective trial shortly! mdpi.com/2072-6694/15/6/1747
1
4
1
18
2,669
Swetha Kambhampati retweeted
Great group at the LRF Sci Res Mentoring Program in Las Vegas @DrCarlaCasulo @SwethaKMD
1
1
1
20
2,562
Swetha Kambhampati retweeted
#Tandem23 | @SwethaKMD of @cityofhope discusses real-world outcomes of patients with transformed R/R DLBCL treated with CAR-T therapy: 👉ow.ly/Hsb550N5GV4👈 @ASTCT @CIBMTR #DLBCL #LymSM #CARTcell #ImmunoOnc
3
2
989
Congrats Carla!
💜 Congratulations @WomenInLymphoma 2023 Steering Committee Chair @DrCarlaCasulo urmc.rochester.edu/people/28… 👏And many thanks 2022 Chair @DrLaCasce for a year packed with growth, accomplishments, advocacy, education & successes #womeninlymphoma #lymphoma @lymphomaOz @URMC_DeptMed
1
7
1,761
Swetha Kambhampati retweeted
Alex (not on Twitter! ) is one of the most passionate and dedicated physician and researcher you will ever meet. I got to know him as classmate and later as co-faculty at ASH CRTI workshop. A true friend and colleague. 🙏🏽🙏🏽👏👏 cc @doctorpemm
2
2
27
7,254
Swetha Kambhampati retweeted
KSHV viral load in CSF predicts involvement by primary effusion #lymphoma KSHV VL >391 copies/mL: Sensitivity=100% Specificity=94% to detect PEL +LR=17 -LR=0 Potential screening tool in low-resource settings with limited pathology services #HIVonc haematologica.org/article/vi…
1
6
2
32
4,047
gene.com/media/press-release… Mosunetuzumab was approved by the FDA hours ago for 3L+ FL! No REMS requirement. So emotional now. Thankful to all the patients enrolled on the trial. Congrats to all my co-investigators, research staff @cityofhope , global sites, @genentech
9
13
1
84
13,093
Swetha Kambhampati retweeted
Reword to add: Please sponsor 'junior FEMALE colleagues' as they are routinely forgotten/overlooked for leadership roles. 70:30 ♂️:♀️ representation in editorial boards. Kudos @HadidiSamer for this insightful study @HemOncWomenDocs @WomeninOnc @WomenInLymphoma @womeninmedchat
This Post is from an account that no longer exists. Learn more
5
9
1,834
So proud to be a part of this wonderful #oncology community! Hoping to serve you all well in this new role.
Dear Colleagues, A warm round of applause to all of those who were chosen at the @ASCO elections 🗳️ Special Kudos to Dr. Robin Zon Elected ASCO President for 2024-2025 & our @OncoAlert 🚨 faculty/friend/colleague @montypal of @cityofhope who enters the nominating committee ‼️
6
7
1
57
7,966